Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

Evanthia Galanis*, S. Keith Anderson, Erin Twohy, Nicholas A. Butowski, Adilia Hormigo, David Schiff, Antonio Omuro, Kurt A. Jaeckle, Shaji Kumar, Timothy J. Kaufmann, Susan Geyer, Priya U. Kumthekar, Jian Campian, Caterina Giannini, Jan C. Buckner, Patrick Y. Wen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)'. Together they form a unique fingerprint.

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

INIS